News

Takeda expands vaccine platform rights with Nanotherapeutics agreement

In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc.

Valneva licenses EB66 technology to develop human, veterinary vaccines

Valneva has already made 5 deals this year licensing the use of its EB66 cell line to develop new vaccines, and now, it is adding two more to the list.

Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials

Pfizer's meningitis B vaccine Trumenba won the FDA's blessing nearly a year ago based on impressive midstage results and national unease about the infection spreading on college campuses. Now, the New York-based pharma announced positive late-stage results on Friday in nearly 7,000 individuals that confirmed the vaccine's effectiveness against certain meningits B strains.

Mathematical models show one dose of Shanchol may be sufficient during epidemics

Shanchol, the cholera vaccine used in endemic countries, is given in two doses 6 weeks apart. But some patients may simply not return for a second dose. If the second dose is delayed by more than 6 weeks, the WHO says, the whole regimen has to be restarted.

FluGen reels in $12M to fund PhI of its universal flu jab

A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.

J&J, Scripps Research Institute test 'universal' flu vaccine in mice, monkeys

The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.

WHO: Vaccine hesitancy is a mounting challenge for immunization programs

Worldwide, 1.5 million children die each year of vaccine-preventable diseases and 1 in 5 children does not get routine immunizations, the WHO says. In a special issue of the journal Vaccine, researchers discussed the role of vaccine hesitancy in limiting vaccine uptake as well as strategies to address it.

Team outlines potential target for aggressive breast cancer vaccine

Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed. 

Pfenex enters anthrax vaccines realm with $143.5M BARDA contract

While San Diego-based Pfenex's primary focus isn't on vaccines, the company gained a big backer in the space Monday with the announcement that the U.S. government has agreed to work with the biotech on its anthrax vaccine candidate for bioterror protection.

NIAID funds Soligenix with $2.7M in ricin vaccine effort

If this week's collaborations are any indication, the U.S. government isn't taking bioterror threats lightly. Just days after a separate agency struck an anthrax vaccine partnership potentially worth $143.5 million, the National Institute for Allergy and Infectious Diseases (NIAID) on Wednesday signed the first contract option in its partnership with Princeton, NJ-based Soligenix to forward work on the company's ricin vaccine candidate RiVax.

Inovio's MERS vaccine shows 100% protection in mice, camels, monkeys

Since 2012, 1,118 cases of Middle East respiratory syndrome (MERS) have been reported in Saudi Arabia and 483 people have died, but there is no vaccine that might head off an outbreak. Among those working to bring a vaccine to market to prevent such an epidemic is Inovio, which announced on Wednesday that its MERS candidate induced 100% protection from a live virus challenge in mice, camels and monkeys.

Bavarian Nordic to start PhI trial of RSV jab

Things are heating up in the race for a respiratory syncytial virus (RSV) vaccine.Novavax reported Phase II results for its investigational vaccine just a week ago, and now, Danish biotech Bavarian Nordic is starting a Phase I trial of its candidate.

Chorus grows for reform in vaccine development process

As the Ebola outbreak continues to wane in West Africa, vaccines experts are combing over what went wrong--and right--with the development of vaccine candidates against the virus.

CMC Biologics to manufacture antibodies for Malaria Vaccines Initiative

GlaxoSmithKline's malaria vaccine, Mosquirix, got an EMA green light just last month, but it doesn't mean efforts to develop additional vaccines have halted. PATH's Malaria Vaccine Initiative (MVI) is teaming up with protein manufacturer CMC Biologics to develop monoclonal antibodies that could inform future development of MVI's malaria candidates.

CSL reports record $1.4B profit following Novartis flu vaccine purchase

CSL is now the second largest flu vaccine manufacturer in the world, thanks to its acquisition of Novartis' flu vaccine business. The company reported a AU$1.9 billion ($1.4 billion) full-year profit, a 6% increase over the previous year.

OSU researchers point to vaccine-free flu protection

Flu vaccines have grown into a multibillion-dollar business, but researchers at the Ohio State University have published findings that could one day transform the field and put a damper on those figures.

The top 5 vaccine makers by 2014 revenue

A recent EvaluatePharma analysis predicts that the top four vaccine makers by 2020 are expected to be within less than one percentage point of market share from each other, and last year's developments in the field may have set the stage for that contest. Here, we break down the top 5 vaccines producers of 2014.

Novavax reports positive top-line data from PhII trial of RSV vaccine

There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.

AZ's MedImmune offers up $727M to get its hands on Inovio cancer vaccine

MedImmune on Monday announced a development deal worth up to $727 million--$27 million upfront--to acquire exclusive rights to Inovio Pharmaceuticals' HPV cancer vaccine INO-3112 and to develop additional cancer vaccine candidates.

U.K.'s Prokarium scores $585,000 for oral chlamydia vaccine

Prokarium, which specializes in developing oral vaccines announced £377,000 ($585,000) in new funding from SynbiCITE, the U.K.'s Innovation and Knowledge Centre for Synthetic Biology. It will go toward the development of an oral chlamydia vaccine.